Date:11/2/2012

dermatology program, $133.4 million, and a $12.0 million payment to terminate a research and development commitment with a third party.(h) Restructuring, acquisition-related and other costs of $47.5 million represent costs related to the acquisitions of Sanitas, Dermik, iNova, Probiotica, OraPharma, University Medical, and Swiss Herbal as well as other internal restructuring and integration initiatives. These include $4.6 million related to acquisition costs, $14.4 million related to employee severance costs, $18.5 million related to integration consulting, duplicative labor, and transition services, $3.8 million related to facility closure costs, and $6.2 million related to other.(i) Restructuring, acquisition-related and other costs of $25.4 million represent costs related to the merger of Legacy Valeant into Legacy Biovail and include $0.9 million related to facility closure costs, $8.9 million related to contract cancellation fees, consulting, legal and other costs, $5.0 million related to severance, $9.5 million related to acquisition costs, and $1.1 million related to manufacturing integration.(j) Non cash interest expense associated with amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest totals for the nine months ended September 30, 2012 and September 30, 2011 are $8.9 million and $12.7 million, respectively.(k) Total tax effect of non-GAAP pre-tax adjustments, resolution of uncertain tax positions and change in valuation allowance associated with deferred tax asset. Valeant Pharmaceuticals International, Inc. Table 2b Reconciliation of GAAP EPS to Cash EPS For the Nine Months Ended September 30, 2012 and 2011Nine Months EndedSeptember 30,(In thousands, except per share data)20122011Product sales$
-$
-Alliance and royalty-804Service and other--Total revenues-804Cost of goods sold (exclusive of amortization of intangible assets shown separately below)(70,435)

 (b)(c)(d) 
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes